Stoke Therapeutics (STOK) Shares Outstanding (2018 - 2026)
Stoke Therapeutics (STOK) posted quarterly Shares Outstanding (Entity) of $62.2 million for Q1 2026, up 14.0% year-over-year from $54.6 million in Q1 2025, and up 5.63% quarter-over-quarter from $58.9 million in Q4 2025.
Stoke Therapeutics (STOK) Shares Outstanding (2018 - 2026) Analysis & Trends
Stoke Therapeutics' Shares Outstanding (Entity) history runs 9 years deep, the most recent figure standing at $62.2 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 14.0% year-over-year to $62.2 million; the TTM figure through Mar 2026 stood at $62.2 million (up 14.0% YoY), while the FY2025 annual figure was $58.9 million, up 9.05% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $62.2 million, up from $58.9 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $62.2 million in Q1 2026, with the low at $39.0 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $46.5 million (2024), against an average of $48.7 million.
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) climbed 19.52% in 2024, then climbed 4.12% in 2025.
- Stoke Therapeutics' Shares Outstanding (Entity) stood at $39.4 million in 2022, then increased by 16.43% to $45.9 million in 2023, then rose by 17.67% to $54.0 million in 2024, then advanced by 9.05% to $58.9 million in 2025, then climbed by 5.63% to $62.2 million in 2026.
- Business Quant data shows STOK's Shares Outstanding (Entity) at $62.2 million in Q1 2026, $58.9 million in Q4 2025, and $55.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Stoke Therapeutics | 1.95 Bn | 1.66 Bn | - | 66.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 66.02 Mn |
| Mar 31, 2026 | 63.06 Mn |
| Dec 31, 2025 | 59.22 Mn |
| Sep 30, 2025 | 58.61 Mn |
| Jun 30, 2025 | 58.35 Mn |
| Mar 31, 2025 | 57.86 Mn |
| Dec 31, 2024 | 54.01 Mn |
| Sep 30, 2024 | 56.34 Mn |
| Jun 30, 2024 | 55.77 Mn |
| Mar 31, 2024 | 46.25 Mn |
| Dec 31, 2023 | 43.99 Mn |
| Sep 30, 2023 | 44.27 Mn |
| Jun 30, 2023 | 44.19 Mn |
| Mar 31, 2023 | 42.54 Mn |
| Dec 31, 2022 | 38.90 Mn |
| Sep 30, 2022 | 39.42 Mn |
| Jun 30, 2022 | 39.26 Mn |
| Mar 31, 2022 | 37.45 Mn |
| Dec 31, 2021 | 36.74 Mn |
| Sep 30, 2021 | 36.76 Mn |